Is it true that venetoclax/venetoclax heals itself?

Venetoclax/Venetoclax is a drug that targets BCL-2 protein and is mainly used to treat hematological malignancies, such as chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). Its mechanism is to target and kill cancerous CLL cells by blocking the BCL-2 protein that regulates B cell survival and death. Overproduction of BCL-2 is common in CLL cells, and blocking it with venetoclax causes the death of these cancer cells. However, venetoclax may also kill healthy B cells.

Venekra is not a drug that can achieve self-healing alone. Its effect depends on various factors such as the individual's condition, immune system status, and characteristics of cancer cells. Although some patients may experience significant clinical improvement after taking venetoclax, and some even achieve complete remission after a period of treatment, this does not mean that all patients will achieve the same effect.

The efficacy of venetoclax usually needs to be combined with other treatments, such as chemotherapy, immunotherapy, etc. In many cases, venetoclax alone may not be able to completely eliminate cancer cells, so doctors often develop a personalized comprehensive treatment plan based on the patient's specific situation. When patients receive any anti-cancer treatment, they should maintain good communication with their doctors, follow up regularly, evaluate the efficacy and adjust the treatment plan.

A patient's self-healing ability is also related to a variety of factors, including age, physical condition, genetic background, etc. After receiving venetoclax treatment, some patients may achieve control or remission of cancer to a certain extent due to the enhancement of the body's immune system or the improvement of its own adaptability. However, this does not mean that all patients can achieve self-healing with venetoclax.

References:https://healthtree.org/cll/guides/cll-fixed-and-continuous-duration-therapy-guide/venetoclax-monotherapy